You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Doctor speaking to a patient
Ready to vaccinate with SHINGRIX (herpes zoster vaccine, recombinant, adjuvanted)?

Get the information you need to administer SHINGRIX to adults 50 years of age and older with confidence.1

Reconstitution Instructions for SHINGRIX

This video will guide you through the reconstitution process for SHINGRIX.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

SHINGRIX prescribing information and adverse event reporting information

POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000

PM-IE-SGX-WCNT-220001 | Date of Preparation: May 2022

Dosing and administration

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1

Making it part of your routine

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1

SHINGRIX vaccine MUST be reconstituted prior to administration.1

Ensuring two-dose schedule completion

For further safety information on SHINGRIX including a full list of adverse reactions reported during post-marketing surveillance, please consult the Summary of Product Characteristics.1

Learn more about SHINGRIX

References

  1. SHINGRIX Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc. Last Accessed May 2022.
  2. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009 137 38-472.
  3. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  4. UK NICE Clinical Knowledge Summaries. What are the complications? October 2020. Accessed May 2021.
  5. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22):2087-96.
  6. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11):1019-32.
  7. Chapter 23, National Immunisation guidelines for Ireland, available on https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter23.pdf Last Accessed: May 2022.
  8. Public Health England Green Book. Immunisation Procedures Chapter 4. Jun 2012.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

SHINGRIX is owned by or licensed to the GSK group of companies. © 2022 GSK group of companies or its licensor. Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-SGX-WCNT-210007 | Date of Preparation: May 2022